Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes.

European journal of haematology - 1 Dec 2021

Song Amy, Altabbakh Omar, Sallman David A, Padron Eric, Talati Chetasi, Hussaini Mohammad O

Abstract excerpt

OBJECTIVES: The presence of targeted therapy, Enasidenib, for IDH2-mutated AML underscores the importance of understanding the clonal dynamics of IDH2 mutations, which has not been elucidated. In the largest study of IDH2 clonal dynamics, we detail the IDH2-evolutionary patterns and their clinical significance. METHODS: We analyzed ~6000 patients with NGS results to identify 120 AML patients with IDH2 mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Isocitrate Dehydrogenase
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Prognosis

Share to Recurrence

Share to Remission Induction

Source

Identifiers

PMID: 34407254
DOI: 10.1111/ejh.13698

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes.PMID 34407254Read ↗

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia.Semantic proximity Read ↗

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.Semantic proximity Read ↗

Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia.Semantic proximity Read ↗

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.Semantic proximity Read ↗

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.Semantic proximity Read ↗

Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes.Semantic proximity Read ↗

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia.Semantic proximity Read ↗

IDH1- and IDH2-mutated myeloid neoplasms: mutational pattern, clonal hierarchy, and the role in AML transformation.Semantic proximity Read ↗

Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL.Semantic proximity Read ↗

Comprehensive analysis of mutations and clonal evolution patterns in a cohort of patients with cytogenetically normal acute myeloid leukemiaSemantic proximity Read ↗

The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AMLSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.